Instalar Timezone Herramienta!
Pulse el botón copiar y pegar en tu blog o sitio web.
(Por favor, cambiar a 'HTML' al modo de desplazamiento en su blog. Ejemplos: Ejemplo WordPress, Ejemplo Blogger)
Sana Biotechnology to Present at March 2026 Investor Conferences SEATTLE, Feb 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March
Sana Biotechnology Reports Third Quarter 2025 Financial Results and . . . Sana expects to file an IND and begin our Phase 1 clinical trial for SC451 as early as 2026 Fusogen Platform – In vivo CAR T cells – SG293 is the next-generation version of our prior SG299 product candidate and was renamed to reflect an updated construct and manufacturing process
Home - Sana Biotechnology Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease
Sana Biotechnology Reports Second Quarter 2025 Financial Results and . . . Sana’s management believes that these non-GAAP financial measures are helpful in understanding Sana’s financial performance and potential future results, as well as providing comparability to peer companies and period over period
Sana Biotechnology Appoints Brian Piper as Executive Vice President . . . SEATTLE, Feb 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer Mr Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in
For Patients - Sana Biotechnology Changing the possible for patients Sana is a science-driven, patient-centric company filled with employees who wake up everyday focused on advancing potentially curative medicines for people in need We know that we must act with urgency and care in moving forward our therapeutics